Program
vasigrobart
Its studies are mostly in Pulmonary Arterial Hypertension, led by Regeneron Pharmaceuticals.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Regeneron Pharmaceuticals | 21 open or running | phase 2since Jan 2, 2026 | Nov 13, 2023 | Feb 27, 2028phase 2 · NCT07318597 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Nov 13, 2023First study: phase 1 study in Healthy VolunteersFirst studyNCT06137482 · 56 enrolled · New Zealand
- Jul 10, 2025Named vasigrobartINNProposed as its International Nonproprietary Name in WHO's List 133 · before, REGN13335
- Jan 2, 2026Phase 2 study in Pulmonary Arterial HypertensionPhase 2 reachedNCT07318597 · 99 planned · United States, Australia, Belgium and more
Ahead
- Feb 27, 2028Primary completion: phase 2 study in Pulmonary Arterial HypertensionNCT07318597
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07318597Pulmonary Arterial Hypertension · United States, Australia, Belgium and more | 2 | Recruiting | Feb 27, 2028 | 99 |
| NCT06137482Healthy Volunteers · New Zealand | 1 | Completed | Feb 11, 2025 | 56 |
How it is read
Names in the registry
- “REGN13335”, 2 entries
Conditions, from the studies’ own filings
- Pulmonary Arterial Hypertension, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.